Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 78 results
Filters: First Letter Of Title is P  [Clear All Filters]
Found 78 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

P

DiRienzo AGregory. "Parsimonious covariate selection with censored outcomes." Biometrics. 2016;72(2):452-62.
Gross R, Zheng L, La Rosa A, et al. "Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234)." Lancet HIV. 2015;2(1):e12-e19.
Freeman ML, Lederman MM, Gianella S. "Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection." Curr HIV/AIDS Rep. 2016;13(1):10-9.
Genberg BL, Wilson IB, Bangsberg DR, et al. "Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America." AIDS. 2012;26(11):1415-23.
Lee AJ, Bosch RJ, Evans SR, et al. "Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen." J. Neurovirol.. 2015;21(2):210-8.
Stewart P, Cachafeiro A, Napravnik S, et al. "Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay." J. Clin. Virol.. 2010;49(3):198-204.
McComsey GA, Kitch D, Sax PE, et al. "Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s." Clin. Infect. Dis.. 2011;53(2):185-96.
Tebas P, Zhang J, Hafner R, et al. "Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110." J. Antimicrob. Chemother.. 2009;63(5):998-1005.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Evans SR, Ellis RJ, Chen H, et al. "Peripheral neuropathy in HIV: prevalence and risk factors." AIDS. 2011;25(7):919-28.
Palmer S, Boltz V, Martinson N, et al. "Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission." Proc. Natl. Acad. Sci. U.S.A.. 2006;103(18):7094-9.
Shivakoti R, Yang W-T, Berendes S, et al. "Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings." J. Infect. Dis.. 2016;213(7):1074-8.
Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.
Wu H, Huang Y, Acosta EP, et al. "Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence." J Pharmacokinet Pharmacodyn. 2006;33(4):399-419.
Haas DW, Bartlett JA, Andersen JW, et al. "Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration." Clin. Infect. Dis.. 2006;43(6):783-6.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Castillo-Mancilla JR, Aquilante CL, Wempe MF, et al. "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)." J. Antimicrob. Chemother.. 2016;71(6):1609-18.
Aweeka FT, Kang M, Yu J-Y, Lizak P, Alston B, Chung RT. "Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team." HIV Med.. 2007;8(5):288-94.
Sha BE, Tierney C, Sun X, et al. "PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150." Jacobs J AIDS HIV. 2015;1(1).
Ma Q, Forrest A, Rosenkranz SL, et al. "Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers." Biopharm Drug Dispos. 2008;29(2):91-101.
Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. "Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108." AIDS. 2006;20(5):725-9.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
Gupta SK, Rosenkranz SL, Cramer YS, et al. "The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis." AIDS. 2008;22(15):1919-27.
Decloedt EH, van der Walt JS, McIlleron H, Wiesner L, Maartens G. "The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals." Int. J. Tuberc. Lung Dis.. 2015;19(10):1194-6.
Gulick RM, Su Z, Flexner C, et al. "Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211." J. Infect. Dis.. 2007;196(2):304-12.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Sherman KE, Kang M, Sterling R, et al. "Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection." World J Hepatol. 2017;9(4):217-223.
Dooley KE, Luetkemeyer AF, Park J-G, et al. "Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin." Antimicrob. Agents Chemother.. 2014;58(9):5245-52.
Para MF, Schouten J, Rosenkranz SL, et al. "Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200." J. Acquir. Immune Defic. Syndr.. 2010;53(4):491-5.
Moore CB, Verma A, Pendergrass S, et al. "Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols." Open Forum Infect Dis. 2015;2(1):ofu113.

Pages